Yelak Biru/LinkedIn
Jun 16, 2025, 16:24
Yelak Biru: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
Yelak Biru, President and Chief Executive Officer at International Myeloma Foundation, posted on X:
“Congratulations Dr. Kaur on this iMMagine-1 study result and presentation at EHA 2025
‘Anito-cel utilizes a novel, synthetic antigen-binding domain called the D-Domain, which allows for high transduction efficiency, CAR positivity, and CAR density on the T-cell surface. Coupled with a fast off rate and ability to detach from the BCMA target, [this provides] us with a safe and efficacious product,’ lead study author Gurbakhash Kaur said during the presentation.
-
Anito-cel achieved a 97% overall response rate in relapsed/refractory multiple myeloma patients with at least three prior therapies, with a stringent complete response rate of 68%.
-
The novel D-Domain in anito-cel enhances transduction efficiency and safety, contributing to its efficacy in the iMMagine-1 trial.
-
Safety data showed manageable cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, with most cases resolving quickly.
-
Anito-cel is being further evaluated in the phase 3 iMMagine-3 trial against standard-of-care therapy for relapsed/refractory multiple myeloma.”
Title: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
Author: Chris Ryan
Read The Full Article at OncLive25.
Find More Posts on Hemostasis Today.
-
Jan 4, 2026, 17:02Oğuzhan Işılay on Stabilizing Human Blood Clotting Factor VIII
-
Jan 4, 2026, 16:48Sleep Apnea: Full Breakdown from John Chuback
-
Jan 4, 2026, 16:36Edwin Ofori Atta on Permissive Hypertension For Ischemic Stroke
-
Jan 4, 2026, 16:27Nasrin Haghani on The Milli-Spinners: Breakthrough Technology Transforming Stroke Clot Removal
-
Jan 4, 2026, 16:10Godfrey Gandawa on Neuroplasticity in Stroke Rehabilitation
-
Jan 4, 2026, 14:53What Do Blood and Plasma Donors Think About Biobanking? A New Study Reveals Their Attitudes
-
Jan 4, 2026, 14:51First Results from the International BPDCN Registry: Data from 36 Patients Across 12 Countries
-
Jan 4, 2026, 14:51Shreya Agrawal: Top 5 Practical Hematology Lessons from 2025 – Mild Cytopenias are Rarely “Incidental” and More
-
Jan 4, 2026, 14:46We Analyzed Data From the Start of the COVID-19 Pandemic to 2024 – What Did We find?